4-苯氧基苯甲醛 | 67-36-7

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香醛(含缩醛,半缩醛)
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-苯氧基苯甲醛
• 中文别名: 对苯氧基苯甲醛
• 英文名称: 4-phenoxy benzaldehyde
• 英文别名: p-phenoxybenzaldehyde；para-phenoxybenzaldehyde；4-benzyloxybenzaldehyde；4-phenyloxybenzaldehyde；4-Phenoxybenzaldehyde
• CAS: 67-36-7
• 化学式: C₁₃H₁₀O₂
• mdl: MFCD00003383
• 分子量: 198.221
• InChiKey: QWLHJVDRPZNVBS-UHFFFAOYSA-N

物化性质

• 熔点：
  24-25 °C (lit.)
• 沸点：
  185 °C/14 mmHg (lit.)
• 密度：
  1.132 g/mL at 25 °C (lit.)
• 闪点：
  >230 °F
• 溶解度：
  可溶于氯仿、甲醇
• 保留指数：
  294.9

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S23,S24/25
• WGK Germany：
  3
• 海关编码：
  2912499000
• 危险品运输编号：
  225kgs
• RTECS号：
  CU7560000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：室温，密封保存。

SDS

Name:	4-Phenoxybenzaldehyde 98% Material Safety Data Sheet
Synonym:	Benzaldehyde,4-phenoxy; 4-formyldiphenylether; p-phenoxybenzaldehyd
CAS:	67-36-7

Section 1 - Chemical Product MSDS Name:4-Phenoxybenzaldehyde 98% Material Safety Data Sheet
Synonym:Benzaldehyde,4-phenoxy; 4-formyldiphenylether; p-phenoxybenzaldehyd

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
67-36-7	4-Phenoxybenzaldehyde	98	200-650-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
No information regarding eye irritation and other potential effects was found.
Skin:
No information regarding skin irritation and other potential effects was found.
Ingestion:
May cause digestive tract disturbances. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 67-36-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear colorless to yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 185 deg C
Freezing/Melting Point: 24.00 - 25.00 deg C
Autoignition Temperature: Not available.
Flash Point: > 112 deg C (> 233.60 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.1320g/cm3
Molecular Formula: C13H10O2
Molecular Weight: 198.22

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 67-36-7: CU7560000 LD50/LC50:
Not available.
Carcinogenicity:
4-Phenoxybenzaldehyde - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 67-36-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 67-36-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 67-36-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-苯氧基苯甲醛 在 盐酸 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 1.0h， 生成 4-苯氧基苯酚
  参考文献：
  名称：

  A Convenient Method for the Preparation of 4-Aryloxyphenols

  摘要：

  本文介绍了一种通过预成苯酚的同系物制备 4-芳氧基苯酚的简便方法。将各种 4-取代苯酚与 4-氟苯甲醛 (8) 或 4-氟苯乙酮 (9) 缩合，可得到相应的 4-芳氧基苯甲醛 10 和苯乙酮 11，收率为 70-93%。用 3-氯过氧苯甲酸（MCPBA）对这些材料进行拜耳-维里格氧化，可得到相应的 4-甲氧基和 4-乙酰氧基苯基醚，这些醚无需纯化即可水解为所需的 4-芳氧基苯酚 12，收率为 72-94%。 4-氟苯甲醛（8）和 4-氟苯乙酮（9）在合成上等同于 a4 umpoled 合成物 6。此外，还介绍了从芳香族二元醇制备 4,4′-[芳基双（氧）]双酚的方法的扩展。将各种芳香族二元醇与 8 或 9 缩合，可得到相应的 4,4′-[芳基双（氧）]双苯甲醚 15 和苯乙酮 16，收率为 71-89%。用 MCPBA 对这些化合物进行 Baeyer-Villiger 氧化，可得到所需的 4,4′-[芳基双（氧）]双苯双甲酸酯 17 和双乙酸酯 18，收率为 67-84%。水解这些化合物可得到所需的 4,4′-[芳基双（氧）]双酚 19，收率为 70-91%。

  DOI：

  10.1055/s-1991-26381
• 作为产物：
  描述：

  4-甲基二苯基醚 在 核黄素,2',3',4',5'-四乙酸酯 作用下， 以 水 、 叔丁醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 生成 4-苯氧基苯甲醛
  参考文献：
  名称：

  黄素光催化甲苯和邻苯二胺有氧交叉脱氢偶联苯并咪唑的简便合成

  摘要：

  在此，我们展示了通过甲苯和邻苯二胺的黄素光催化有氧氧化交叉脱氢偶联来实现苯并咪唑的绿色原子经济合成。所提出的无金属反应在可见光照射下在甲醇/H 2 O 中进行，仅消耗大气中的分子氧并仅产生水作为废物。

  DOI：

  10.1039/d3ob00113j
• 作为试剂：
  描述：

  Boc-O-甲基-L-酪氨酸 、 N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 、 2-咪唑甲醛 在 哌啶 、 N-甲基吡咯烷酮 、 4-二甲氨基吡啶 、 4-苯氧基苯甲醛 、 sodium cyanoborohydride 、 溶剂黄146 、 N,N-二异丙基乙胺 、 甲胺 、 三氟乙酸 、 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 DMF (N,N-dimethyl-formamide) 、 1,2-二氯丙烷 、 二氯甲烷 为溶剂， 反应 48.0h， 生成 (S,S)-6-{4-[(1H-imidazol-2-ylmethyl)-amino]-butyl}-3-(4-methoxy-benzyl)-1-(4-phenoxy-benzyl)-piperazine-2,5-dione
  参考文献：
  名称：

  [EN] 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY
  [FR] COMPOSES DESTINES AU TRAITEMENT DE L'OBESITE

  摘要：

  公开号：

  WO2004048345A3

文献信息

• Cyclopropyl derivative lipoxygenase inhibitors
  申请人：Abbott Laboratories

  公开号：US05037853A1

  公开（公告）日：1991-08-06

  Certain carbocyclic aryl- and heterocyclic aryl-substituted cyclopropyl N-hydroxyureas, N-hydoroxycarboxamides, and N-acyl-N-hydroxyamides inhibit 5- and/or 12-lipoxygenase and are useful in the treatment of inflammatory disease states.

  某些含环丙基N-羟基脲、N-羟基羧酰胺和N-酰基-N-羟基酰胺的碳环芳基和杂环芳基取代物抑制5-和/或12-脂氧合酶，在治疗炎症性疾病状态中具有用处。
• [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
  申请人：REMYND NV

  公开号：WO2016083490A1

  公开（公告）日：2016-06-02

  This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。
• [EN] PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE 1-[(3R)-3-[4-AMINO-3-(4-PHÉNOXYPHÉNYL)-1H- PYRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPÉRIDINYL]-2-PROPÈN-1-ONE ET DE SES POLYMORPHES
  申请人：MSN LABORATORIES PRIVATE LTD

  公开号：WO2016170545A1

  公开（公告）日：2016-10-27

  The present invention relates to an improved process for the preparation of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)- 1 H-pyrazolo[3,4-d]pyrimidin- 1 -yl]- 1 -piperidin yl]-2-propen-1-one compound of formula- 1 and its polymorphs thereof, which is represented by the following structural formula:

  本发明涉及一种改进的制备1-[(3R)-3-[4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]-1-哌啶基]-2-丙烯-1-酮化合物及其多晶形式的方法，其由以下结构式表示：
• Copper-Catalyzed Transfer Hydrodeuteration of Aryl Alkenes with Quantitative Isotopomer Purity Analysis by Molecular Rotational Resonance Spectroscopy
  作者：Zoua Pa Vang、Albert Reyes、Reilly E. Sonstrom、Martin S. Holdren、Samantha E. Sloane、Isabella Y. Alansari、Justin L. Neill、Brooks H. Pate、Joseph R. Clark

  DOI：10.1021/jacs.1c00884

  日期：2021.5.26

  A copper-catalyzed alkene transfer hydrodeuteration reaction that selectively incorporates one hydrogen and one deuterium atom across an aryl alkene is described. The transfer hydrodeuteration protocol is selective across a variety of internal and terminal alkenes and is also demonstrated on an alkene-containing complex natural product analog. Beyond using 1H, 2H, and 13C NMR analysis to measure reaction

  描述了一种铜催化的烯烃转移加氢氘化反应，该反应选择性地将一个氢和一个氘原子结合到芳基烯烃上。转移加氢氘化协议对各种内部和末端烯烃具有选择性，并且还在含烯烃的复杂天然产物类似物上得到了证明。除了使用1 H、2 H 和13C NMR 分析测量反应选择性，六转移氢化氘化产物通过分子旋转共振 (MRR) 光谱分析。通过与高通量样品分析兼容的测量方法，进一步探索了 MRR 光谱在氘化学中同位素杂质分析中的应用。在第一步中，使用宽带啁啾脉冲傅立叶变换微波光谱仪分析反应化学中所有同位素变体的 MRR 光谱特征。有了签名，就可以创建测量脚本，使用商用腔增强 MRR 光谱仪对样品成分进行定量分析。使用该仪器的样品消耗量低于 10 毫克，分析时间约为 10 分钟 - 与宽带 MRR 光谱相比，两者都代表了数量级的减少。迄今为止，这些测量代表了转移加氢氘化反应中选择性的最精确的光谱测定，并确认在这种温和的协议下可以实现
• [EN] 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS<br/>[FR] DERIVES DE 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT DE DOULEUR OU DE TROUBLES GASTRO-INTESTINAUX
  申请人：ASTRAZENECA AB

  公开号：WO2004041801A1

  公开（公告）日：2004-05-21

  Compounds of general formula:[Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  通式化合物：[化学式应在此处插入。请参阅纸质副本]其中R1、R2和R3如规范中定义，以及其盐、对映体和包括该化合物的药物组合物已经制备。它们在治疗中很有用，特别是在疼痛管理中。

表征谱图